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effective. Univariate sensitivity analyses showed that changes in the costs of atorvas-
tatin, and in treatment duration have the biggest impact on the results. Subsequent 
probabilistic analyses will be used to further explore uncertainties around the 
estimates.
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OBJECTIVES: To estimate the cost effectiveness of rivaroxaban against enoxaparin 
for the prophylaxis of venous thromboembolism (VTE) in patients after total hip 
replacement (THR) in Slovakia from payer perspective. METHODS: A cost-utility 
model based on results of large randomized controlled trial (RECORD 1) was devel-
oped. In RECORD1, patients received 35 days prophylaxis with rivaroxaban or 
enoxaparin. Rivaroxaban reduced total VTE (composite: any DVT, non-fatal PE, 
all-cause mortality) by 70% versus enoxaparin after 35 days prophylaxis. The model 
was divided into three parts: prophylaxis, post-prophylaxis, and long-term complica-
tions. The ﬁrst two parts represents acute phase and were modeled as a decision tree. 
Third part represents the long-term complications and was developed as a Markov 
model. The ﬁrst part of the model is populated by RECORD 1 trial, while published 
epidemiological and clinical data estimating the risk of further VTE events and post-
thrombotic syndrome beyond the trial period were used in second and third part of 
the model. Local cost data was based on published price lists, clinical guidelines, 
product labels and expert opinion. VTE related utilities were used from literature. 
Effectiveness was measured in quality-adjusted life years (QALY). Time horizon was 
set at 5 years and payers perspective was used. Discount rate was 7% per year for 
costs and effects according to Ministry of Health (MoH) guidelines for health eco-
nomic evaluation valid in 2008. One-way and probabilistic sensitivity analyses were 
performed. RESULTS: Rivaroxaban was cost-effective versus enoxaparin, with an 
incremental cost per QALY of 39672.10. This is signiﬁcantly below ofﬁcially pub-
lished 326,500 /QALY threshold for willingness to pay in Slovakia. Over 1,000 
samples of probabilistic sensitivity analysis, 633 simulations were below a threshold 
of 326,500. CONCLUSIONS: Rivaroxaban is a cost-effective alternative to enoxapa-
rin for the prevention of VTE following THR in Slovakian setting.
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OBJECTIVES: Aspirin prevents myocardial infarction (MI), but increases gastrointes-
tinal bleeding (GIB) and dyspepsia. Proton pump inhibitors (PPIs) reduce GIB risk and 
dyspepsia, but economic implications of use with aspirin has not been studied. We 
examine cost-utility of low-dose aspirin + PPI (omeprazole) 20 mg daily; low-dose 
aspirin alone; or no therapy for primary cardiovascular (CVD) prevention. METHODS: 
We develop a Markov model and performed a lifetime analysis of middle-aged and 
older men without history of CVD at levels of 10-year risk for coronary heart disease 
(CHD) events from 2.5% to 25%, using a third-party payer perspective. Baseline risks 
of MI, stroke, and CHD death were estimated from Framingham equations. Baseline 
risks of GIB and dyspepsia were estimated from cohort studies. Non-cardiovascular 
mortality obtained from US life tables. From systematic reviews, aspirin reduced CHD 
events by 30%, increased total stroke risk by 6%, increase risk of dyspepsia by 80%, 
and increase risk of GIB 2-fold for patients without history of GIB and 10-fold for 
patients with history of GIB. Addition of PPI reduced GIB risk by 90% and dyspepsia 
by 50%. RESULTS: For the base case of 45-year-old men with 10-year risk for CHD 
events of 10%, aspirin alone was more effective and less costly than no treatment. 
Aspirin + PPI (compared with aspirin alone) had cost/QALY of $473,673 when 
dyspepsia is not modeled and $51,059 when the effects of treating dyspepsia are 
included. The incremental cost/QALY of adding PPI was found to improve as CHD 
or GIB risk increases. CONCLUSIONS: Aspirin for CHD prevention is cost-saving in 
men over 45 with a 10-year CHD risk of 10% or greater. When the beneﬁts from 
treating dyspepsia are not included, adding PPI is not cost-effective as a routine means 
of preventing GI bleeding. The cost-effectiveness of adding PPI to aspirin is dependent 
on PPI cost and protective effect against GI adverse events.
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OBJECTIVES: Regadenoson, a newer adenosine derivative, has improved pharmaco-
logic properties that may improve safety proﬁle and administrative requirements 
compared to adenosine and dipyridamole. This study assessed the economic beneﬁts 
of utilizing regadenoson in myocardial perfusion imaging (MPI). METHODS: Data 
on the overall laboratory and individual staff time spent on MPI procedures and 
managing adverse events was collected from 141 cardiovascular laboratories. Direct 
laboratory MPI cost was estimated by applying hourly labor and fringe beneﬁt rates 
to the amount of time each staff was involved in the test. In addition, the cost of the 
agent and its administration also was applied. Regression analysis was used to examine 
the association between laboratory characteristics and the weekly number of tests. 
The estimated adjusted mean values were used to test the sensitivity of results to this 
parameter. RESULTS: Assuming a set number of 20 tests/week with adenosine and 
dipyridamole, shorter overall test time with regadenoson (mean [± SD] of 156 ± 46 
minutes vs. 182 ± 63 minutes with adenosine and 191 ± 61 minutes with dipyridamole) 
and utilization less of laboratory resources resulted in an additional 177 and 244 tests/
year with regadenoson vs. other agents, respectively. The annual savings with regad-
enoson were $17,377 vs. adenosine and $36,677 vs. dipyridamole in laboratory 
personnel cost and $91,165 vs. adenosine in total cost. Regadenoson resulted in 
$112,134 higher annual total cost compared to dipyridamole due to higher drug-
related costs. CONCLUSIONS: The ﬁndings from this analysis suggest that regadeno-
son will reduce the direct cost of MPI by decreasing the procedure and monitoring 
time and increasing patient throughput. These ﬁndings will be of interest to laboratory 
administrators and payers.
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OBJECTIVES: Previous studies suggest prasugrel may be cost effective when com-
pared to clopidogrel for treating acute coronary syndrome patients (ACS). Recent 
research has shown that the reduced function allele CYP2C19*2 (*2 allele) is associ-
ated with an increased risk of adverse events for ACS patients taking clopidogrel and 
a decreased risk for patients taking prasugrel. The purpose of this paper is to test 
whether using clopidogrel for all patients is cost effective compared to prasugrel for 
*2 allele patients in combination with clopidogrel for non *2 patients and to prasugrel 
only for New Zealand. METHODS: Effectiveness of clopidogrel and prasugrel from 
published TRITON-TIMI 38 clinical trials was combined with rates of *2 occurrence 
in Maori, Paciﬁc Islanders, Asian and NZ European and national hospital records on 
rates and costs of hospitalisations 15 months post ACS for stroke, MI, bleeding, stent 
thrombosis and cardiovascular death. Decision tree modelling and Monte Carlo simu-
lations examined the robustness of the results. RESULTS: Rates of the *2 allele differ 
signiﬁcantly between NZ European (15%), Maori (24%), Asian (29%) and Paciﬁc 
People (45%). Analysis of hospital records suggest that rates of MI, stroke, bleeding, 
stent thrombosis and cardiovascular death were much higher in the general New 
Zealand population than in the clinical trial population. The cost effectiveness analysis 
suggests that use of a genetic test to guide combined use of clopidogrel and prasugrel 
was cost effective for most age and ethnic groups, but particularly for Maori males 
(NZ$3184/QALY), Maori females (NZ$3687/QALY), Paciﬁc men (NZ$4617/QALY) 
and Paciﬁc women (NZ$7605/QALY). Prasugrel is more costly and less effective than 
clopidogrel. CONCLUSIONS: The results here suggest that the use of a genetic test 
to guide treatment decisions for ACS patients is cost effective, especially for Maori 
and Paciﬁc peoples, and that prasugrel alone is not cost effective in New Zealand.
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OBJECTIVES: To estimate the clinical and economic outcome of treatment with 
atorvastatin 80 mg versus simvastatin 40 mg and pravastatin 40 mg in Swedish 
patients with acute coronary syndrome (ACS). Simvastatin 40 mg was selected for the 
analysis based on current clinical treatment practices. METHODS: Efﬁcacy is esti-
mated based on a Bayesian meta-analysis linking decrease in LDL cholesterol levels 
to decreases in secondary cardiovascular (CV) events (MIs, strokes, CV deaths) 
drawing data from statin trials in ACS (MIRACL, PROVE-IT, AtoZ) and using priors 
from published statin meta analyses (CTT, Law). A Markov model combines estimates 
of the occurrence of later events; Swedish cost data; and quality of life. Baseline risks 
are taken from the ACS CURE study. Analyses are conducted using a baseline event 
risk during the ﬁrst 6 months of 12.1% and of 3.89% during later months. The time 
horizon of the analyses is lifetime (50 years). RESULTS: Treatment with atorvastatin 
during the acute phase (three months after event) instead of the comparator yields a 
cost per QALY of 68,784 Swedish kronor (SEK) compared with simvastatin, and of 
45,342 SEK compared with pravastatin. Taking mandatory price cuts of 70% at LOE 
into account, the cost per QALY for lifetime treatment with atorvastatin is 46,056 
SEK compared with simvastatin, and 28,113 SEK compared with pravastatin. ICERs 
improve when risk with age is reduced, lower discount rates are used, and when 
atorvastatin cost is decreased. CONCLUSIONS: Preliminary ﬁndings show that, based 
on currently accepted Swedish cost effectiveness thresholds, using atorvastatin 80 mg 
to treat high risk Swedish ACS patients is a cost-effective intervention, either versus 
simvastatin or pravastatin. Univariate sensitivity analyses showed that changes in the 
costs of atorvastatin, and in treatment duration have the biggest impact on the results. 
